Medicare Part D coverage · sorafenib · RxCUI 615979
sorafenib 200 MG Oral Tablet [Nexavar]
Per the CMS 2026 Part D formulary file, sorafenib 200 MG Oral Tablet [Nexavar] is covered by 12 Medicare Part D plans (0.2% of enrollable products), averaging Tier 3, with prior authorization required on 100% of covering formularies.
- 0.2%
- Plan coverage
- 12
- Plans covering
- T3
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for sorafenib 200 MG Oral Tablet [Nexavar]
Per the CMS 2026 Part D formulary file, sorafenib 200 MG Oral Tablet [Nexavar] (RxNorm concept RXCUI 615979, generic name sorafenib) appears on 2 distinct formulary files spanning 12 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.
Real-world access to sorafenib 200 MG Oral Tablet [Nexavar] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 916 Part D beneficiaries filled sorafenib 200 MG Oral Tablet [Nexavar] in 2023, with total plan-and-beneficiary spending of $32,402,948 and an average per-beneficiary annual cost of $35,374.40. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry sorafenib 200 MG Oral Tablet [Nexavar] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 12
- Coverage rate
- 0.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 916
- Total spending
- $32,402,948
- Avg per beneficiary
- $35,374.40
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering sorafenib 200 MG Oral Tablet [Nexavar]
12 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | Hamaspik, Inc. | T1 | Yes | $34.50 | NY |
| Health First Rewards H1099-014 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First SunSaver H1099-016 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Complete Care H1099-023 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-024 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-025 (HMO-POS) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-026 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-027 (HMO-POS) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-028 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Value H1099-006 (HMO) | Health First Health Plans | T5 | Yes | $15.00 | FL |
| Health First Classic H1099-001 (HMO-POS) | Health First Health Plans | T5 | Yes | $49.40 | FL |
Frequently Asked Questions
Is sorafenib 200 MG Oral Tablet [Nexavar] covered by Medicare Part D?
Yes, sorafenib 200 MG Oral Tablet [Nexavar] is covered by 12 Medicare Part D plans (0.2% of all Part D formularies).
What tier is sorafenib 200 MG Oral Tablet [Nexavar] on Medicare Part D plans?
sorafenib 200 MG Oral Tablet [Nexavar] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 5.
Does sorafenib 200 MG Oral Tablet [Nexavar] require prior authorization?
100% of Part D formularies require prior authorization for sorafenib 200 MG Oral Tablet [Nexavar]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on sorafenib 200 MG Oral Tablet [Nexavar]?
In 2023, total Medicare Part D spending on sorafenib 200 MG Oral Tablet [Nexavar] was $32,402,948, covering 916 beneficiaries. The average spend per beneficiary was $35,374.40.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- sodium phenylbutyrate 0.483 MG/MG Oral Pellet [Pheburane] 100% PA
- formoterol fumarate 0.01 MG/ML Inhalation Solution [Perforomist] 100% PA
- lusutrombopag 3 MG Oral Tablet [Mulpleta] 100% PA
- 12 HR tapentadol 100 MG Extended Release Oral Tablet [Nucynta] 100% PA
- {14 (24 HR lamotrigine 100 MG Extended Release Oral Tablet [Lamictal]) / 7 (24 HR lamotrigine 200 MG Extended Release Oral Tablet [Lamictal]) / 14 (24 HR lamotrigine 50 MG Extended Release Oral Tablet [Lamictal]) } Pack [Lamictal XR Green Patient Titration Kit (for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone, and Not Taking Valproate)] 100% PA
- eltrombopag 25 MG Oral Tablet [Promacta] 100% PA